Nasdaq:US$8.86 (+0.23) | HKEX:HK$13.22 (-0.58) | AIM:£1.63 (+0.04)
News & Presentations
Previous Article   |   Next Article
Presentations | 22 Jan 2022

ASCO GI 2022 | Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer